| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNISA996331946903316 |
|
|
Autore |
Golla Korbinian |
|
|
Titolo |
Hesiods Erga : Aspekte ihrer geistigen physiognomie / / Korbinian Golla |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Berlin, [Germany] ; ; Boston, [Massachusetts] : , : De Gruyter, , 2016 |
|
©2016 |
|
|
|
|
|
|
|
|
|
ISBN |
|
3-11-045703-2 |
3-11-045736-9 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (316 p.) |
|
|
|
|
|
|
Collana |
|
Beiträge zur Altertumskunde, , 1616-0452 ; ; Band 351 |
|
|
|
|
|
|
Classificazione |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Didactic poetry, Classical - History and criticism |
Fate and fatalism in literature |
Mind and body in literature |
Schicksal |
Verstand |
LITERARY CRITICISM / Ancient & Classical |
Criticism, interpretation, etc. |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Frontmatter -- Vorwort -- Inhalt -- I. Prolegomena ad Hesiodi Erga -- 1. Captatio lectoris benevolentiae -- 2. Hinführung -- 3. Vorüberlegungen - Rahmenbedingungen hesiodischen Dichtens -- II. Intellektuelle Grundlagen -- 1. Das Erga-Proömium - Dichtung und Wahrheit -- 2. Seelisch-Geistiges und Condicio humana -- III. Analysen zentraler Sinneinheiten: ,Weltaltermythos' und ,Bauernkalender' -- 1. ,Weltaltermythos' (op. 106-201) -- 2. ,Bauernkalender' (op. 383-617/694) -- IV. Schlussbetrachtung -- V. Verzeichnisse |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
Im frühgriechischen Denken nimmt die Idee der Abhängigkeit menschlichen Lebens von ihn übersteigenden Mächten eine zentrale Stellung ein; der Mensch wird als weitgehend passiv verstanden. Anders Hesiod: Hinter seinen Erga steht das Bild eines aktiven, gestaltenden Menschen, der die Möglichkeit besitzt, sich für ein bestimmtes Handeln - gut wie schlecht - zu entscheiden. Die Entscheidung trifft sein nous |
|
|
|
|
|
|
|
|
|
|
|
|
|
(Verstand), der "das eigentliche Selbst des Menschen" (Arbogast Schmitt) darstellt. Soll Handeln erfolgreich sein, muss es sich innerhalb der auf klaren Regeln beruhenden dike-Ordnung (Recht, Gerechtigkeit) bewegen; so kann der Mensch seine Zukunft weitgehend selbst gestalten und seine Ziele (ökonomisch, sozial) verwirklichen. Weil er erkennen kann, was schlecht ist, existiert auch kein scheinbar irrational waltendes Schicksal: Er ist nicht mehr nur Verantwortlicher (wie im homerischen Epos), er ist schuldig (aitios) an dem durch ihn in Gang gesetzten Geschehen. Vorliegende Untersuchung geht nicht nur dieser neuartigen Sichtweise nach, sondern zeigt auch, dass dem nous die Schlüsselfunktion für die adäquate Rezeption der Erga zukommt, die als Vereinigung unterschiedlicher Gattungen Hesiods bereits in der Theogonie erhobenen Anspruch, neuartige Dichtung zu schaffen, einlöst. |
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910136407603321 |
|
|
Autore |
Jan Trost Jorgensen |
|
|
Titolo |
Drug-diagnostics co-development in oncology [[electronic resource] /] / topic editor Jan Trøst Jørgensen |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Frontiers Media SA, 2014 |
|
France : , : Frontiers Media SA, , 2014 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (111 pages) : colour illustrations, charts |
|
|
|
|
|
|
Collana |
|
Frontiers Research Topics |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references. |
|
|
|
|
|
|
Sommario/riassunto |
|
The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for |
|
|
|
|
|
|
|
|
|
|
tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest™, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs. |
|
|
|
|
|
| |